GlassScriptPhysician profile
Hossein Amirani
NPI 1164493201
$17,916.50
in general payments reported to CMS, 2019-2025
40 companies · $3,052 in 2025
The $3,052 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,464 · 2020: $1,089 · 2021: $2,170 · 2022: $3,191 · 2023: $1,329 · 2024: $5,622 · 2025: $3,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,138 · Travel and Lodging: $3,671 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,138.28 |
| Travel and Lodging | $3,671.46 |
| Education | $192.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $6,370.75 | 2019-2025 | Aveir, Cardiomems, Jot Dx |
| Medtronic, INC. | $5,382.66 | 2021-2025 | Micra, Resolute Onyx, Linq II |
| Astrazeneca Pharmaceuticals LP | $752.13 | 2019-2025 | Farxiga |
| Medtronic Vascular, INC. | $633.21 | 2019-2020 | |
| Organogenesis INC. | $526.95 | 2024-2025 | Nushield, Puraply Wound Matrix, Apligraf |
| Cvrx, INC. | $422.72 | 2021-2025 | Barostim Neo System |
| Philips North America LLC | $408.23 | 2019-2025 | Extended Holter |
| Amgen INC. | $399.91 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.41 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $321.32 | 2020-2025 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $282.93 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $246.01 | 2021-2025 | Verquvo |
| Pfizer INC. | $239.15 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $166.83 | 2022-2025 | |
| Edwards Lifesciences Corporation | $166.39 | 2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hossein Amirani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.